GlassScriptPhysician profile
Steven J Goodnow
NPI 1720433410
$803.93
in general payments reported to CMS, 2019-2025
15 companies · $1.22 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $174 · 2021: $193 · 2022: $135 · 2023: $52.22 · 2024: $147 · 2025: $1.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $132.28 | 2023-2024 | Ffrct |
| Novo Nordisk INC | $119.28 | 2019-2021 | |
| Abbvie INC. | $96.88 | 2022 | |
| Daiichi Sankyo INC. | $85.38 | 2020-2022 | |
| Glaxosmithkline, LLC. | $83.03 | 2020-2021 | |
| Amarin Pharma, INC. | $71.90 | 2020-2021 | |
| Pfizer INC. | $64.92 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $32.95 | 2024 | Arcalyst |
| Lilly USA, LLC | $26.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.45 | 2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.91 | 2024-2025 | Lifevest |
| Advanced Respiratory, INC | $16.72 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.04 | 2019 | |
| Merck Sharp & Dohme LLC | $12.90 | 2020 | |
| Allergan, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Goodnow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.